Pharmachem launches new diabetes management product
The ingredients have shown to lower both circulating glucose and insulin levels after consumption of a 70-gram sucrose challenge, compared to placebo, in two separate human studies. The
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The agreement will leverage the enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients. DSM Pharmaceutical Products CEO Alexander Wessels said, "Via this agreement,
Afrezza is an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s to-be-marketed next-generation inhaler. MannKind chairman and chief executive officer Alfred Mann said the completion of the